# B-MAD Chemotherapy in Newly-diagnosed Extranodal NK/ T-cell Lymphoma

> **NCT03246750** · PHASE1,PHASE2 · COMPLETED · sponsor: **The Thai Lymphoma Study Group** · enrollment: 34 (actual)

## Conditions studied

- Extranodal NK/T-cell Lymphoma

## Interventions

- **DRUG:** B-MAD chemotherapy

## Key facts

- **NCT ID:** NCT03246750
- **Lead sponsor:** The Thai Lymphoma Study Group
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-01-30
- **Primary completion:** 2024-04-10
- **Final completion:** 2024-04-10
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2024-04-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03246750

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03246750, "B-MAD Chemotherapy in Newly-diagnosed Extranodal NK/ T-cell Lymphoma". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03246750. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*